Single-cell and spatial mapping of liver degeneration and regeneration

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study will collect preoperative peripheral blood and discarded liver tissue from patients undergoing hepatectomy or liver biopsy across a range of ages and disease stages, aiming for a repository of 160–240 cases. Researchers will apply single-cell transcriptomics, chromatin accessibility assays, and spatial omics to define cell types, states, and their spatial arrangements in healthy, aging, fatty liver, HBV-infected, fibrotic, and cirrhotic livers. By comparing cellular phenotypes, functions, spatial distributions, and intercellular interactions across groups, the project aims to build a spatiotemporal atlas of liver degeneration and regeneration. No experimental treatments will be given as part of the protocol; clinical care is provided by the treating physician as appropriate.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntarily signed the informed consent form;
2. No restrictions on age and gender;
3. Patients diagnosed with hepatic hemangioma or focal nodular hyperplasia of the liver in accordance with the "Guidelines for the Diagnosis and Treatment of Focal Liver Lesions (2014 Edition)" and the "Guidelines for the Diagnosis and Treatment of Hemangiomas and Vascular Malformations (2019 Edition)";
4. Patients with hepatic hemangioma, focal nodular hyperplasia of the liver, fatty liver, HBV infection, liver fibrosis, and cirrhosis who clinically require liver surgery or liver biopsy.

Exclusion Criteria:

1. Individuals with concurrent infections such as HIV will be excluded.
2. Patients with coagulation system disorders, such as hemophilia or idiopathic thrombocytopenic purpura, will not be included.
3. Those with severe underlying diseases that affect the body's immune status will be excluded.
4. Individuals whom the investigator deems unsuitable for participation in this study will be excluded.

Where it's running

• Nan
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Yongyin Li, Dr.
• Email: yongyinli@foxmail.com
• Phone: +8613826039505

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD

  This program automatically screens high‑risk adults aged 50–75 in primary care to see if they have advanced liver fibrosis and possible MASLD, using routine blood tests and reflex lab tests without extra work for clinicians.

  Recruiting Hospital General Universitario Gregorio Marañon · Madrid, Madrid · NCT07658755

• Screening for advanced liver fibrosis in patients with fatty liver disease or alcohol-related liver issues

  This study is testing two blood tests to see which one better helps doctors find advanced liver damage in people with fatty liver disease or alcohol-related liver problems.

  Recruiting University Hospital, Angers · Angers and 12 other locations · NCT05699018

• Endohepatology-based reclassification of treatment indication in high-risk MASLD

  This study tests whether an endohepatology assessment can change treatment decisions for adults with high-risk MASLD.

  Recruiting University Hospital Muenster · Münster · NCT07877272

• Umbilical cord stem cells added during Kasai to help biliary atresia

  This early-stage trial tests whether injecting umbilical cord mesenchymal stem cells during Kasai portoenterostomy is safe and helpful for infants with biliary atresia.

  Recruiting Phase 1 Dr Cipto Mangunkusumo General Hospital · Jakarta Pusat, DKI Jakarta · NCT07797673

• Hernic/Hecn30227 injection in healthy people and chronic hepatitis B patients

  This study tests whether a single and multiple doses of HECN30227 injections are safe and how the body handles and responds to them in healthy volunteers and in people with chronic hepatitis B.

  Recruiting Phase 1 Sunshine Lake Pharma Co., Ltd. · Hefei · NCT07771140

• ECC4703 with Sulfasalazine and Pitavastatin in adults with NAFLD and dyslipidemia

  This early study tests whether adding ECC4703 to sulfasalazine and pitavastatin is safe and how the body handles the combination in adults with fatty liver disease and high cholesterol.

  Recruiting Phase 1 Eccogene · Melbourne, Victoria · NCT07726368

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.